Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment

European Heart Journal

Volumn 36, Issue 43, 2015, Pages 2975-2983

  Soran, Handrean ^a,b   Schofield, Jonathan D ^a,b   Durrington, Paul N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cardiovascular risk calculation Primary prevention Number needed to treat

Indexed keywords

CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER PROGRAM; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; CLINICAL DECISION MAKING; METABOLISM; NUMBERS NEEDED TO TREAT; PRIMARY PREVENTION; PROCEDURES; RISK ASSESSMENT; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL DECISION-MAKING; EZETIMIBE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NUMBERS NEEDED TO TREAT; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS;

EID: 84983095344     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv340     Document Type: Review

References (29)

1. National Institute for Health and Clinical Excellence (NICE) clinical guideline 67. Lipid modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Developed by the National Collaborating Centre for Primary Care. https://www.nice. org.uk/guidance/cg67 (accessed 15 July 2015).
2. National Cholesterol Education Program. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
3. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Perrone Filardi P, Riccardi G, Storey RF, Wood D. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Europ Heart J 2011;32:1769-1818.
4. Wood DA, Wray R, Poulter N, Williams B, Kirby M, Patel V, Durrington P, Reckless J, Davies M, Sivers F, Potter J. JBS2: Joint British guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl. V):v1-v52.
5. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. 2013 ACC/AHA guidance on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 PtB): 2889-2934.
6. NICE. Lipid modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. https://www.nice.org.uk/guidance/cg181 (accessed 15 July 2015).
7. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985;14:32-38.
8. Godlee F. Adverse effects of statins. BMJ 2014;348:g3306.
9. Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 2014;12:51.
10. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197.
11. Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.
12. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipo-protein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-1427.
13. http://www.qrisk.org (accessed 15 July 2015).
14. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guidelines on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2014;129:S49-S73.
15. Expert Dyslipidemia Panel of the International Atherosclerosis Society. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia-full report. J Clin Lipidol 2014;8:29-60.
16. Soran H, Schofield JD, Durrington P. The importance of considering low-density lipoprotein cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy. Curr Opin Lipidol 2014;25:239-246.
17. Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, Durrington PN, Chilcott J. Ezetimibe monotherapy for cholesterol lowering in 2722 people: systematic review and meta-analysis of randomized controlled trials. J Int Med 2009; 265:568-580.
18. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density lipoprotein and very-low-density lipoprotein and their risk predictive values in coronary heart disease. Am J Cardiol 2006;98:1363-1368.
19. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009;53:316-322.
20. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014;100(Suppl. 2):ii1-ii67.
21. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA 2013;310:2061-2068.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
23. Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert KA. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104: 1577-1579.
24. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998; 97:1436-1439.
25. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55, 000 vascular deaths. Lancet 2007;370:1829-1839.
26. Chaudhury M. Blood analytes. In: Sproston K, Primatesta P (eds). Health Survey for England 2003. Risk Factors for Cardiovascular Disease, vol. 2. London: The Stationery Office; 2004. p241-287.
27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
28. van Kempen BJ, Ferket BS, Hofman A, Spronk S, Steyerberg E, Hunink MG. Do different methods of modeling statin treatment effectiveness influence the optimal decision? Med Decis Making 2012;32:507-516.
29. Kavousi M, Leening MJ, Nanchen D, Greenland P, Graham IM, Steyerberg EW, Ikram MA, Stricker BH, Hofman A, Franco OH. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014;311:1416-1423.